26 August 2025 - Bayer today announced that a new drug application for its investigational contrast agent gadoquatrane has been accepted for review by the US FDA.

The new drug application for gadoquatrane has been filed for contrast-enhanced magnetic resonance imaging of the central nervous system and other body regions in adults and paediatric patients including neonates.

Read Bayer press release